Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Nickol, Gary B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S377000
Reexamination Certificate
active
07897570
ABSTRACT:
The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or decrease expression or function depending on the condition being treated.
REFERENCES:
patent: 7341997 (2008-03-01), Bartlett et al.
patent: 2008/0254023 (2008-10-01), Bartlett et al.
patent: 2008/0255044 (2008-10-01), Bartlett et al.
patent: WO-96/09384 (1996-03-01), None
patent: WO-6/135518 (1996-05-01), None
patent: WO-96/23000 (1996-08-01), None
patent: WO-96/26958 (1996-09-01), None
patent: WO-97/04091 (1997-02-01), None
patent: WO-97/14966 (1997-04-01), None
Martone et al., Brain research, (Oct. 17, 1997) vol. 771, No. 2, pp. 238-250.
Flanagan & Vanderhaeghen, Annual Review of Neuroscience, 21:309-345 (1998).
Park, et al., “Aberrant axonal projections in mice lacking EphA8 (Eek) tyrosine protein kinase receptors”,EMBO Journal, 16(11):3106-3114 (1997).
Smith, et al., “The EphA4 and EphB1 receptor tyrosine kinases and ephrin-B2 ligand regulate targeted migration of branchial neural crest cells”,Current Biology, 7(8):561-570 (1997).
Richard WS Tsika, Ph.D., “Transgenic Animal Models”,Exercises and Sport Science Reviews, 22:361-388 (1994).
Holland, et al., “Cell-contact-dependent signaling in axon, growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase”,Current Opinion in Neurology, 8(1):117-127 (1998).
Brambilla, R. et al., “Telling axons where to grow: a role for Eph receptor tyrosine kinases in guidance”,Mol. Cell Neurosci., 6:487-495 (1995).
Tessier-Lavigne, M., Eph receptor tyrosine kinases, axon repulsion, and the development of topographic maps,Cell, 82:345-348 (1995).
Friedman, G. C. et al., “Eph receptor tyrosine kinases and their ligands in neural development”, Curr. Opin Neurobiol., 6:127-133 (1996).
Cheng, H. J. et al., “Complementary gradients in expression and binding of ELF-1 and Mek4 in development of the topographic retinotectal projection map”, Cell, 82:371-381 (1995).
Drescher, U. et al., “In vitro guidance of retinal ganglion cell axons by RAGS, and 25kDa tectal protein related to ligands for Eph receptor tyrosine kinases”, Cell. 82:359-370 (1995).
Nakamoto, M. et al.“Topographically specific effects of ELF-1 on retinal axon guidance in vitro and retinal axon mapping in vivo”, Cell, 86:755-766 (1996).
Henkemeyer, M. et al., “Nulk controls pathfinding of commissural axons in mammalian central nervous system”, Cell, 86:35-46 (1996).
Orioli, D. et al., Sek4 and nuk receptors cooperate in guidance of commissural axons and in palate formation EMBO J, 15:6035-6049 (1996).
Orioli, D. et al., “The Eph receptor family: axonal guidance by contact repulsion”, T I G, 13:354-359 (1997).
Gale, N. W. et al., “Eph receptors and ligands comprise two major specifically subclasses and are reciprocally compartmentalized during embryogenesis”, Neuron, 17:9-19 (1996).
Gale, N. W. et al. “Elk-:L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segments”, Oncogene, 13:1343-1352 (1996).
Bergemann, A. D. et al., “Ephrin-B3, a ligand for the receptor EphB3, expressed at the midline of the developing neural tube”,. Oncogene, 16:471-480 (1998).
Nieto, M. A. et al, “A receptor protein tyrosine kinase implicated in the segmental patterning of the hindbrain and mesoderm”, Development, 116:1137-1150 (1992).
Mori, et al., “Differential expression of the eph family of receptor tyrosine kinase genes (sek, elk, eck) in the developing nervous system of the mouse”, Brain Res. Mol. Brain Res.. 29:325-335 (1995).
Xu, Q. et al., “Expression of truncated Sek-1 receptor tyrosine disrupts the segmental restriction of gene expression in the Xenopus and zebrafish hindbrain”, Development, 121:4005-4016 (1995).
Xu, Q et al., “Function of the Eph-related kinase rtk1 in patterning of the zebrafish forebrain”, Nature, 381:319-322 (1996).
Stanfield, B. B., “The development of the corticospinal projection”, Prog. Neurobiol., 38:169-202 (1992).
Irving, C. et al., “Progressive spatial restriction of SEk-1 and Krox-20 gene expression during hindbrain segmentation”, Dev. Biol., 173:26-38 (1996).
Robb, L. et al., “Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene”, Proc Natl Acad Sci USA, 92 7075-7079 (1995).
Lyons, I. et al. “Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene”, Genes & Dev. 9:1654-1666 (1995).
Schaeren-Wiemers, N. et al., “A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes”, Histochemistry, 100:431-440 (1993).
Galea, M. et al., “Corticospinal projection patterns following unilateral section of the cervical spinal cord in the newborn and juvenivle macaque monkey”, Comp. Neurol., 381:282-306 (1997).
Rees, S. et al., “The structural and functional development of muscle spindles and their connections in fetal sheep”, Brain Res., 642:185-198 (1994).
Adams, J. et al., “Heavy Metal Intensification of DAB-based HRP reaction product”, Histochem. Cytochem., 29(6):775 (1981).
Capecchi, M. R.,. “Altering the genome by homologous recombination”, Science, 244: 1288-1292 (1989).
DeFries, J. et al., “Response to 30 generations of selection for open-field activity in laboratory mice”, Behavioural Genetics, 8(1):3-13 (1978).
Bregman, B. S. et al., “Anatomical plasticity and sparing of function after spinal cord damage in neonatal cats”, Science, 217:553-555 (1982).
Bregman, B. S. et al., “Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors”, Nature, 378:498-501 (1995).
Casale, E. J. et al., “Direct projection of the corticospinal tract to the superficial laminae of the spinal cord in the rat”, Comp Neurology, 278:275-286 (1988).
Cohen, N. R. et al., “Errors in corticospinal axon guidance in mice lacking the neural cell adhesion molecule L1”, Curr. Biol., 8:26-33 (1997).
Bastmeter. M. et al., “Dynamics of target recognition by interstitial axon branching along developing cortical axons”, Neurosci., 16:1450-1459 (1996).
Holland. S. J. et al., “Bidirectional signaling through the EPH-family receptor Nuk and its transmembrane ligands”, Nature, 383: 722-725 (1996).
Bruckner, K. et al., “Tyrosine phosphorylation of transmembrane ligands for Eph receptor”, Science, 275:1640-1643 (1997).
Ohta, K. et al., “The inhibitory effect on neurite outgrowth of motoneurons exerted by the ligands ELF-1 and RAGS”, Mech. Dev. 64:127-135 (1997).
Wang, H. U. et al., “Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth”, Neuron, 18:383-396 (1997).
Richards, L. J. et al., “Directed growth of early cortical axons is influenced by a chemoattractant released from an intermediate target”, Neurosci. 17(7):2445-2458 (1997).
Gilardi-Hebenstreit, P. et al., “An Eph-related receptor protein tyrosine kinase gene segmentally expressed in the developing mouse hindbrain”, Oncogene, 7:2499-2506 (1992).
Laird, P. W. et al.,. Simplified mammalian DNA isolation procedure, Nucleic Acids Res., 19:4293 (1991).
Lackmann, M. et al. “Distinct subdomains of the Eph3 receptor mediate ligand binding and receptor dimerization”, J. Biol. Chem., 273(32):20228-2
Bartlett Perry F.
Boyd Andrew W.
Coonan Jason
Dottori Mirella
Galea Mary P.
Foley & Lardner LLP
Gamett Daniel C
Nickol Gary B.
The Council of the Queensland Institute of Medical Research
The University of Melbourne
LandOfFree
Method of treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2708614